Preview Mode Links will not work in preview mode


Hosted by Editor in Chief Lorenzo Norris, MD, Psychcast features mental health care professionals discussing the issues that most affect psychiatry.

Apr 3, 2019

Charles Raison, MD, returns to the Psychcast this week to give a Masterclass lecture on the bidirectional relationship between inflammation and depression. There are links to relevant research below.


Dr. Raison discusses incorporating the science of inflammation into the pharmacologic treatment of depression. He addresses research suggesting that while depression as a whole isn’t an inflammatory condition, inflammation may be a depressive subtype. He also covered how inflammation might affect treatment.

You can listen to Dr. Raison's take-home messages by skipping to (19:45). 




Dr. Raison is Mary Sue and Mike Shannon Chair for Healthy Minds, Children, & Families and Professor of Human Development and Family Studies at the  School of Human Ecology as well as Professor in the Department of Psychiatry at the University of Wisconsin-Madison School of Medicine and Public Health.


Dr. Raison previously appeared on Psychast in a two-part lecture on ketamine. In episode 14, Dr. Raison talked on ketamine and PTSD and in episode 15, he talked about ketamine and depression. You can find those episodes by clicking the links below:


Psychcast Episode 14: Charles Raison, MD, Ketamine & PTSD.

Psychcast Episode 15: Charles Raison, MD, Ketamine & depression.



Relevant Research:

Use these links to find more on this Masterclass. 

Rong, Carola, et al. Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder. Int J Environ Res Public Health. 2018 Apr 17:15(4): doi: 10.3390/ijerph15040771.

Savitz, JB et al. Treatment of Bipolar Depression With Minocycline and/or aspirin: an adaptive, 2x2 double-blind, randomized, placebo-controlled, phase II-A clinical trial. Transl Psychiatry. 2018 Jan 24;8(1):27. doi: 10.1038/s41398-017-0073-7.

Raison, et al. A Randomized Controlled Trial of the Tumor Necrosis Factor-alpha Antagonist Infliximab in Treatment Resistant Depression: Role of Baseline Inflammatory Biomarkers. JAMA Psychiatry. 2013 Jan;70(1):31-41.

Miller AH, Raison CL. Are Anti-inflammatory Therapies Viable Treatments for Psychiatric Disorders?: Where the Rubber Meets the Road. JAMA Psychiatry. 2015 Jun; 72(6): 527–528.

Adzic M, et al. Therapeutic Strategies for Treatment of Inflammation-related Depression. Curr Neuropharmacol. 2018 Jan 30;16(2):176-209.